Blockchain Identity: Securing Pharma Supply Chains

Excluded from normalized aggregate trends after staff review: 3056 posts were attributed to March 2026; 671 shared March 14, 2026. The preceding six-month median was 13.5 posts.

Review evidence: 3,056 posts in March 2026; 671 shared March 14, 2026; preceding six-month median 13.5. Reviewed August 9, 2026.

This company's pages remain public, but its content is excluded from normalized aggregate trends. Unfiltered raw trends and advanced filtering are available to Accelerate and Lead accounts.

Blockchain-based pharmaceutical supply chains can create immutable, time-stamped records of products from raw-material sourcing through dispensing, improving traceability, data integrity, recall precision, regulatory reporting, and detection of counterfeit or diverted medicines. The approach is presented as an alternative to centralized databases that may be more vulnerable to tampering, fraud, and single points of failure, while supporting serialization requirements under regulations such as the U.S. Drug Supply Chain Security Act and Europe’s Falsified Medicines Directive. Because a blockchain’s reliability depends on the legitimacy of those entering information, the text positions Didit as an identity layer for manufacturers, distributors, logistics providers, pharmacists, and healthcare professionals. Its tools include document-based ID verification using OCR, MRZ, and barcode scans, passive and active liveness checks, face matching, and AML screening and monitoring, which are intended to prevent impersonation and ensure authorized participants interact with the system. Didit also describes its modular, API-first platform, no-code business console, and free KYC tier as ways to integrate identity checks into blockchain supply-chain workflows.

Use this post, company, and trend context to find content marketing opportunities, perform competitive analysis, or address product feature gaps via the Plushcap MCP server or the Plushcap API.